Organogenesis Holdings (ORGO) AI Stock Analysis

• Market Cap: $602.55M
• Dividend Yield: N/A
• Average Volume (3M): 917.48K
• Price to Earnings (P/E): 928.6
• Beta (1Y): 1.64
• Revenue Growth: 5.35%
• EPS Growth: -432.51%
• Country: US
• Employees: 869
• Sector: Healthcare
• Sector Strength: 37
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.17
• Shares Outstanding: 126,853,540
• 10 Day Avg. Volume: 941,813
• 30 Day Avg. Volume: 917,476
• PEG Ratio: -0.27
• Price to Book (P/B): 1.32
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -38.71
• Enterprise Value/Market Cap: 0.81
• Enterprise Value/Revenue: 0.26
• Enterprise Value/Gross Profit: 1.42
• Enterprise Value/Ebitda: 42.96
• 1Y Price Target: $6.25
• Price Target Upside: 31.58% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 58 Neutral
• Price Target: $5.00 ▲(5.26%Upside)

The overall stock score of 57.8 reflects significant financial challenges with declining revenue and profitability. However, strong technical momentum and strategic initiatives outlined in the earnings call provide a basis for cautious optimism. Poor valuation metrics underscore the need for careful consideration.

Positive Factors

Financial Stability

The recent debt reduction by Organogenesis Holdings has contributed to a higher price target, reflecting improved financial stability.

Market Position

ORGO is one of three companies listed on both the DFU and VLU covered lists, suggesting strong positioning in the market.

Product Pricing

NuShield experienced a significant average sales price increase, moving to $530.00 from $92.65.

Negative Factors

Regulatory Challenges

Despite good performance, LCDs and sales risks remain an overhang on shares, potentially limiting stock value growth.

Sales Guidance

Management's revised sales guidance implies a significant back-end weighted ramp, which in our view adds a degree of risk in hitting full year targets.

Uncertainty in Regulation

ORGO's 1Q25 results were negatively impacted by continued LCD uncertainty regarding skin substitute grafts, where implementation has been delayed a third time to January 1, 2026.

Organogenesis Holdings Business Overview & Revenue Model

Company Description

Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.

How the Company Makes Money

Organogenesis Holdings Inc. generates revenue primarily through the sale of its advanced wound care and surgical biologics products. The company's revenue streams are largely driven by the commercialization of its proprietary technologies, which include bioactive wound healing and tissue repair solutions. Organogenesis partners with healthcare providers, hospitals, and clinics to provide these products for patient care, establishing contracts and agreements that facilitate widespread distribution. Additionally, the company invests in research and development to expand its product offerings and enhance its competitive position in the regenerative medicine market. Significant factors contributing to its earnings include a growing demand for effective wound care solutions and strategic partnerships that enhance product reach and adoption.

Organogenesis Holdings Financial Statement Overview

Summary

Organogenesis Holdings shows a mix of strengths and weaknesses in its financial performance. While the company maintains a strong gross profit margin and a low debt-to-equity ratio, it faces challenges with declining revenue, profitability, and negative cash flow. The declining equity and liquidity issues further highlight operational inefficiencies that need addressing.

Income Statement

Organogenesis Holdings experienced a decline in revenue with a negative growth rate of around -4.82% from 2024 to TTM (Trailing-Twelve-Months), alongside a consistent downward trajectory since 2021. The company shows negative net profit margins and EBIT margins in the TTM, indicating operational challenges. However, gross profit margins remain strong at 74.89% in TTM, suggesting efficient cost management. Despite strong historical performance, recent declines highlight potential risks.

Balance Sheet

The balance sheet reflects moderate stability with a debt-to-equity ratio of 0.18 in TTM, showcasing low leverage and prudent financial management. The equity ratio stands at 51.96%, indicating a healthy proportion of equity within the asset structure. However, declining stockholders' equity and rising liabilities over the periods pose risks to financial stability. The return on equity is negative in TTM, further pointing to profitability issues.

Cash Flow

The cash flow analysis reveals challenges with negative free cash flow in TTM, deteriorating from previous periods, indicating liquidity issues. The operating cash flow to net income ratio is 0.24, highlighting operational inefficiencies. While past periods showed positive free cash flow, recent figures suggest potential cash constraints, necessitating careful liquidity management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	458.76M	482.04M	433.14M	450.89M	468.06M	338.30M
Gross Profit	343.58M	366.30M	326.66M	345.87M	353.86M	250.98M
EBITDA	-15.55M	15.76M	36.03M	40.32M	87.00M	37.23M
Net Income	-18.63M	861.00K	4.95M	15.53M	94.20M	17.23M
Balance Sheet
Total Assets	467.39M	497.89M	460.02M	449.36M	443.26M	294.49M
Cash, Cash Equivalents and Short-Term Investments	109.97M	135.57M	104.34M	102.48M	113.93M	84.39M
Total Debt	42.63M	43.31M	119.35M	123.79M	132.30M	84.77M
Total Liabilities	99.33M	112.57M	181.36M	183.69M	201.22M	148.41M
Stockholders Equity	242.90M	385.32M	278.66M	265.67M	242.03M	146.08M
Cash Flow
Free Cash Flow	-7.00M	4.18M	6.55M	-9.04M	30.76M	-14.34M
Operating Cash Flow	4.43M	14.21M	30.92M	24.86M	61.98M	6.80M
Investing Cash Flow	-11.44M	-10.03M	-24.36M	-33.90M	-31.22M	-24.83M
Financing Cash Flow	28.19M	27.64M	-5.50M	-2.20M	-1.04M	42.47M

Organogenesis Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.75
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORGO, the sentiment is Positive. The current price of 4.75 is above the 20-day moving average (MA) of 4.23, above the 50-day MA of 3.54, and above the 200-day MA of 3.76, indicating a bullish trend. The MACD of 0.32 indicates Negative momentum. The RSI at 69.23 is Neutral, neither overbought nor oversold. The STOCH value of 91.70 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ORGO.

Organogenesis Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COLL	75 Outperform	$1.03B	26.46	19.23%	―	17.17%	-51.97%
AVDL	67 Neutral	$1.07B	―	-34.65%	―	252.64%	85.10%
PAHC	67 Neutral	$1.19B	38.12	11.86%	1.61%	19.12%	141.45%
HROW	61 Neutral	$1.37B	―	-37.23%	―	53.49%	33.18%
ORGO	58 Neutral	$602.55M	928.57	-4.92%	―	5.35%	-432.51%
Sector *	52 Neutral	$7.61B	0.10	-63.03%	2.08%	16.34%	0.32%
EOLS	44 Neutral	$622.19M	―	-949.46%	―	25.38%	15.00%

Organogenesis Holdings Corporate Events

Organogenesis Holdings Approves Key Proposals at Annual Meeting

On June 23, 2025, Organogenesis Holdings held its Annual Meeting of Stockholders where several key proposals were voted on and approved. The meeting included the re-election of Garrett Lustig to the board of directors and the election of other directors to serve until the next annual meeting. Additionally, stockholders approved the compensation for named executive officers and the issuance of over 20% of Class A common stock upon conversion of Series A Convertible Preferred Stock, which may be deemed a change of control under Nasdaq rules. The appointment of RSM US LLP as the independent registered public accounting firm for 2025 was also ratified.

The most recent analyst rating on (ORGO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Organogenesis Holdings stock, see the ORGO Stock Forecast page.